I nnate immunity is the first defence line of a host against invading microbes 1, 2 . The innate immune system utilizes germline-encoded pattern recognition receptors (PRRs), including membrane-bound Toll-like receptors and cytosolic retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), to detect foreign pathogen invasion. Pathogen-associated molecular patterns derived from bacterial and viral elements are recognized by host PRRs 3 . All RLRs harbour a DEAD/H-box RNA helicase domain that binds to dsRNA. RIG-I and MDA5, sensors of RNA virus infection, contain an N-terminal tandem CARD domain that is critical to initiate type I interferon (IFN) secretion [4] [5] [6] . Once binding to viral RNAs, RIG-I and MDA5 undergo conformational change to activate another CARD-containing adaptor protein, mitochondrial antiviral signalling protein (MAVS, also known as VISA, IPS-1 and CARDIF) [7] [8] [9] [10] . Then MAVS activates IRF3 and NF-kB to produce type I IFNs and other cytokines [11] [12] [13] , leading to further activation of the adaptive immunity and restriction of the infection.
To avoid damage to the host from excessive inflammation, antiviral signalling requires tight regulation to adequately eradicate invading pathogens. Given that MAVS coordinates signals from two independent central PRRs, the cell employs various mechanisms to modulate MAVS, including proteinprotein interactions, changes of mitochondrial dynamics and post-translational modifications 12 . Recently, several negative regulators for MAVS have been reported [14] [15] [16] [17] . Among these negative regulators, the host RNA-binding protein PCBP2 (poly(rC) binding protein 2) was originally identified to be involved in host cell mRNA stability and translational regulation of cellular mRNAs 18 . During virus infection, PCBP2 can associate with MAVS that acts as a scaffold to enhance AIP4-mediated degradation of MAVS 17 . Endogenous PCBP2 primarily resides in the nucleus but relocalizes to the cytoplasm where it initiates MAVS degradation on viral infection. However, the underlying mechanism by which PCBP2 undergoes nuclear export during virus infection is still unknown.
Insulin receptor tyrosine kinase substrate (IRTKS), a member of the IRSp53/MIM family, plays a pivotal role in the formation of plasma membrane protrusions 19 . It has been reported that IRTKS directly mediates the clustering of actin filaments 20 , and initiates pathogen-driven actin pedestal formation on bacterial infection 21, 22 . In addition, IRTKS can be phosphorylated in response to insulin stimulation 20 . Moreover, IRTKS deficiency causes insulin resistance 23 . Insulin resistance might be implicated in clinical infections and immune regulations. However, whether IRTKS is involved in the regulation of innate immunity remains elusive. Here we show that IRTKS deficiency augments innate immune responses against RNA viruses. IRTKS mediates sumoylation of PCBP2 to cause its nuclear export on RNA virus infection, leading to MAVS degradation.
Results
IRTKS deficiency enhances anti-RNA virus activity. We previously generated IRTKS knockout mice and found that IRTKS deletion exhibits insulin resistance 23 . Given that insulin resistance might be implicated in clinical infections, we then wanted to explore whether IRTKS was involved in the antimicrobial response. First, IRTKS was successfully deleted in bone marrow-derived macrophages (BMDMs) and mouse embryonic fibroblasts (MEFs) of IRTKS À / À mice (Fig. 1a , left panel). We observed that the survival rate of IRTKS À / À mice was similar to that of littermate control mice on infection with Listeria monocytogenes (Fig. 1a, right panel) .
We next wanted to test whether IRTKS deficiency influenced the host's antiviral activity. We infected IRTKS À / À mice with several RNA and DNA virus strains. Interestingly, IRTKS À / À mice were more resistant to RNA virus vesicular stomatitis virus (VSV) infection compared with littermate IRTKS þ / þ mice (Fig. 1b) . However, when treated with DNA viruses such as herpes simplex virus (HSV), survival rates were similar between IRTKS þ / þ and IRTKS À / À mice ( Supplementary Fig. 1a ). These data indicate that IRTKS À / À mice display enhanced antiviral activity against RNA viruses.
Type I IFNs are major cytokines to induce antiviral responses in the host 1, 24 . With VSV infection, IRTKS À / À mice expectedly produced higher levels of type I IFNs in sera than their littermate control mice (Fig. 1c,d ). Consistently, viral titres were markedly declined in various tissues of IRTKS À / À mice compared with IRTKS þ / þ mice ( Fig. 1e and Supplementary Fig. 1b,c) . To further confirm the IRTKS deficiency-enhanced immune response against RNA viruses, we assayed IFN levels in IRTKS À / À macrophages post viral stimulation. As expected, IRTKS À / À macrophages generated higher levels of type I IFNs than those of their littermate control mice (Fig. 1f,g ). Consequently, VSV replication was remarkably suppressed in IRTKS À / À macrophages (Fig. 1h) . Similarly, IRTKS À / À macrophages also produced higher levels of type I IFNs on Sendai virus (SeV) challenge ( Supplementary Fig. 1d ,e) and IRTKS À / À mice were resistant to SeV infection ( Supplementary  Fig. 1f ). By contrast, IRTKS deletion displayed no significant antiviral change compared with wild-type (WT) mice during DNA virus infection ( Supplementary Fig. 1g-l) . Taken together, IRTKS functions as an inhibitory modulator in the clearance of RNA viruses.
IRTKS suppresses antiviral immunity via RIG-I-MAVS.
The induction of type I IFNs is modulated by transcription factors, including NF-kB and the IFN regulatory factors IRF3 and IRF7 (ref. 1). Activation of IRF3 and IRF7 needs phosphorylation by two IKK-related kinases, TBK1 and IKK 25 . On phosphorylation, these two IRFs undergo homodimerization and translocate into the nucleus, leading to the transcription of type I IFN genes. We then examined the activation of IRF3 in IRTKS À / À BMDMs during virus challenge. As expected, RNA viruses were able to initiate enhanced activation of IRF3 in IRTKS À / À macrophages and produced elevated levels of IFNs in these cells (Fig. 2a) . However, DNA viruses had no such activity (Fig. 2a) . In addition, IRTKS knockout sustained high levels of IFN expression after VSV infection (Fig. 2b) . By contrast, for IRTKS þ / þ cells, Ifnb mRNA levels were increased at early time points, whereas decreased at late time points post VSV challenge (Fig. 2b) . Consequently, the replication of VSV in IRTKS À / À cells was remarkably suppressed (Fig. 2c) . However, IRTKS deficiency did not affect the IFN expression with HSV infection ( Supplementary  Fig. 2a ) or the replication of HSV in these cells ( Supplementary  Fig. 2b ). Since poly(dA:dT) can be converted to 5 0 -ppp RNA by RNA polymerase III (ref. 26) , we then utilized poly(dA:dT) and poly(I:C) to mimic RNA virus infection. Similarly, poly(I:C) and poly(dA:dT) triggered robust activation of IRF3 and produced elevated levels of IFNs in IRTKS À / À macrophages (Fig. 2d) . By contrast, poly(dI:dC) and calf thymus DNA, mimicking viral DNAs, did not promote enhanced IRF3 transcription in IRTKS À / À macrophages.
On RNA virus infection, RIG-I and MDA5 activate MAVS through the CARD-CARD interaction 1, 27 . MAVS in turn triggers the activation of NF-kB and IRF3, suggesting the RIG-I-MAVS pathway is major means to clear RNA viruses. To determine whether IRTKS-mediated suppression of innate immunity depends on the RIG-I-MAVS signalling, we co-transfected MEF cells with increasing amounts of IRTKS plus members of the RIG-I-MAVS pathway. We found that IRTKS overexpression markedly inhibited IFN-b production induced by RIG-I and MAVS, but not by TBK1 or TRAF3 (Fig. 2e) . However, IRTKS overexpression showed inhibitory effect on MDA5-mediated Ifnb expression ( Supplementary Fig. 2c ), but it did not block Ifnb expression even with a highest dose of IRTKS transfection during the period of VSV infection. These data are in agreement with a previous report showing that MDA5 has a distinct function from RIG-I in the innate immune response 28, 29 . Moreover, IRTKS significantly suppressed endogenous Ifnb expression elicited by RIG-I and MAVS, but not by TBK1 or TRAF3 in macrophages (Fig. 2f) . In addition, IRTKS overexpression remarkably inhibited Ifnb expression in macrophages with VSV infection (Fig. 2g) . Similar observations were also achieved in poly(I:C)-or poly(dA:dT)-treated cells, but not in poly(dI:dC)-or calf thymus-DNA-treated cells (Supplementary Fig. 2d ).
We next knocked down RIG-I or MAVS through shRNAs in IRTKS-deficient BMDMs (Fig. 2h) . We noticed that RIG-I or MAVS knockdown almost blocked Ifnb expression in IRTKSdeficient cells (Fig. 2i) . Altogether, IRTKS-mediated suppression of antiviral response relies on the RIG-I-MAVS signalling pathway.
IRTKS interacts with PCBP2. To elucidate the IRTKS-mediated suppression of antiviral response, we screened a mouse cDNA library derived from murine bone marrow using IRTKS as a bait through a yeast two-hybrid approach. Seven positive clones were identified to be PCBP2, a negative regulator of MAVS 17 . Their interaction of IRTKS with PCBP2 was verified by the yeast twohybrid assay (Fig. 3a) . Moreover, recombinant IRTKS also associated with PCBP2 through a glutathione S-transferase (GST)-based pull-down assay (Fig. 3b) . Notably, the association of IRTKS with PCBP2 was only observed in cells infected with VSV virus (Fig. 3c) . In addition, the interaction of IRTKS with PCBP2 was significantly enhanced over the process of VSV infection (Fig. 3d) . However, DNA viruses such as HSV virus failed to mediate this interaction (Fig. 3e) . These data indicate that RNA viruses induce the interaction of IRTKS with PCBP2 during virus infection. Using truncated IRTKS fragments, we mapped IRTKS (amino acid (aa) 400-514) was necessary and sufficient for association with PCBP2 (Fig. 3f,g ). Importantly, restoration with the deleted IRTKS (IRTKS(D400-514)) did not rescue the suppression of VSV infection in IRTKS-deficient macrophages (Fig. 3h) . However, restoration of the full-length (FL) IRTKS (IRTKS-FL) displayed robust VSV infection. These data suggest that the aa 400-514 fragment is necessary for IRTKS-mediated suppression of virus infection. Similarly, using truncated PCBP2 fragments, we defined PCBP2 (aa 1-81) was necessary and sufficient for interaction with IRTKS ( Fig. 3i,j) . Consistently, restoration of the deletion of aa 1-81 of PCBP2 (PCBP2(D1-81)) failed to rescue the suppression of VSV infection in PCBP2-silenced macrophages (Fig. 3k) . Overall, the interaction of IRTKS with PCBP2 plays a critical role in the suppression of RNA virus infection.
IRTKS promotes PCBP2-mediated degradation of MAVS.
PCBP2 is known to augment MAVS degradation for immune regulation during RNA infection 17 . The association of IRTKS with PCBP2 prompted us to examine whether IRTKS regulated the protein stability of MAVS as well. As expected, IRTKS knockout prohibited the degradation of MAVS in BMDMs during VSV challenge (Fig. 4a ). This degradation took place at the protein level, but not at the mRNA level ( Supplementary Fig. 3a) . Moreover, the proteasome inhibitor MG132 could block the degradation of MAVS (Fig. 4b) , suggesting MAVS was degraded by the proteasome pathway. Consistently, K48-linked polyubiquitinated MAVS appeared in IRTKS þ / þ BMDMs on VSV infection (Fig. 4c) , whereas IRTKS À / À cells displayed a very ARTICLE weak signal. More importantly, IRTKS overexpression facilitated MAVS degradation with a dose-dependent manner in macrophages on VSV challenge (Fig. 4d) . However, IRTKS overexpression did not affect the mRNA stability of MAVS ( Supplementary Fig. 3b ). These results suggest that IRTKS enhances proteasome-mediated degradation of MAVS during virus infection. Of note, IRTKS overexpression failed to induce MAVS degradation in PCBP2-depleted macrophages (Fig. 4e) , suggesting that IRTKS-mediated suppression of antiviral response depends on PCBP2. It has been reported that PCBP2 plays a pivotal role in the degradation of MAVS 17 . They also demonstrated that Lys371 and Lys420 of MAVS are the two residues for K48-linked polyubiquitination. We then generated the degradation-resistant mutant K371R/K420R-MAVS and overexpressed it in macrophages. We observed that IRTKS did not induce the degradation of K371R/K420R-MAVS even in shCtrl-treated macrophages (Fig. 4f) . However, IRTKS potentiated the degradation of WT MAVS only in the presence of PCBP2. We then rescued PCBP2(FL) or PCBP2(D1-81) in PCBP2-silenced BMDMs. PCBP2(D1-81) restoration failed to induce the degradation of MAVS post virus stimulation (Fig. 4g) . Consequently, PCBP2(D1-81) restoration did not inhibit MAVS-mediated type I IFN generation (Fig. 4h) . By contrast, PCBP2(FL) restoration remarkably prohibited type I IFN production. Finally, IRTKS(D400-514) restoration could not induce the degradation of MAVS on virus stimulation either (Fig. 4i) . Consistently, IRTKS(D400-514) restoration did not suppress MAVS-mediated type I IFN production (Fig. 4j) . Altogether, IRTKS potentiates the degradation of MAVS through interaction with PCBP2.
IRTKS recruits Ubc9 to sumoylate PCBP2 on virus infection. Among the positive clones screened out from the above yeast two-hybrid assay, 21 clones were identified to be Ubc9. The interaction of IRTKS with Ubc9 was validated by yeast twohybrid assay (Fig. 5a ). We then mapped the Ubc9-binding site on IRTKS. We noticed that the aa 1-230 fragment of IRTKS was necessary and sufficient for interacting with Ubc9 (Fig. 5b) . More importantly, with VSV stimulation, anti-IRTKS antibody was able to precipitate Ubc9 and PCBP2 in macrophages (Fig. 5c ), suggesting that IRTKS associated with Ubc9 and PCBP2 during virus challenge. Ubc9 is the only E2 ligase for protein sumoylation 30, 31 . Then we examined whether PCBP2 or IRTKS underwent sumoylation during virus infection. Interestingly, we observed that PCBP2 was sumoylated on VSV challenge (Fig. 5d) . Treatment with the sumoylation inhibitor ginkgolic acid 32 blocked the sumoylation of PCBP2. During VSV infection, polysumoylated PCBP2 was further verified by immunoblotting with anti-PCBP2 or anti-small ubiquitin-like modifier 2 (anti-SUMO2) antibody ( Supplementary Fig. 4a,b) . Furthermore, PCBP2 sumoylation was caused by SUMO2, but not by SUMO1 ( Supplementary Fig. 4c,d ), which was validated by immunoblotting with anti-HA antibody. These data suggest that PCBP2 undergoes SUMO2-mediated polysumoylation during virus infection. We next wanted to determine the cellular location in which PCBP2 was sumoylated on VSV infection. We infected BMDMs with VSV virus and performed fractionation of the cytoplasm and nucleus during early and late time points. At 1 h post VSV infection, PCBP2 sumoylation appeared in the nucleus, not detectable in the cytoplasm (Fig. 5e) . However, at 8 h after VSV infection, PCBP2 sumoylation mainly existed in the cytoplasm (Fig. 5e) , whereas only weak signals were picked in the nucleus. With treatment of the nuclear export inhibitor leptomycin B before VSV infection, PCBP2 sumoylation only appeared in the nucleus at 8 h, but no sumoylated signals in the cytoplasm (Fig. 5e ). These data indicate that the PCBP2 sumoylation takes place in the nucleus during VSV infection. Notably, PCBP2 and Ubc9 were mainly localized in the nucleus in Mock-treated BMDMs (Fig. 5f ). Whereas IRTKS distributed in the nucleus and cytoplasm. At early time post VSV infection, PCBP2, Ubc9 and IRTKS exhibited colocalization in the nucleus of BMDMs (Fig. 5f) . Furthermore, VSV particles entered into the nucleus and colocalized with these proteins at an early stage of VSV challenge ( Supplementary Fig. 4e) .
We further verified our observations with an in vitro reconstitution assay. We found that PCBP2 could be sumoylated by Ubc9 with the in vitro assay (Fig. 5g) . Lysine 37 was predicted to be the only sumoylation site on PCBP2 through a GPS-antismall ubiquitin-like modifier (SUMO) predicting tool 33 . We generated several PCBP2 mutants carrying lysine to arginine mutations. As expected, the K37R mutation impaired the sumoylation of PCBP2 via the in vitro assay (Fig. 5g) . More importantly, IRTKS was required for the sumoylation of PCBP2 (Fig. 5g) . Without IRTKS, PCBP2 did not undergo sumoylation. Expectedly, IRTKS deficiency abrogated the sumoylation of PCBP2 with VSV challenge (Fig. 5h) , which maintained the stability of MAVS. Finally, Ubc9 depletion also abolished the PCBP2 sumoylation (Fig. 5i) . Taken together, IRTKS recruits Ubc9 to sumoylate PCBP2 in the nucleus on RNA virus infection.
IRTKS promotes PCBP2 translocation and MAVS degradation.
It has been reported that protein sumoylation is involved in the nuclear-cytoplasmic transport of various proteins 34, 35 . Given that MAVS is a mitochondrial membrane adaptor, the interaction of PCBP2 with MAVS requires the nuclear export of PCBP2. Therefore, we next examined whether the sumoylation of PCBP2 triggered its cytoplasmic translocation. Expectedly, VSV stimulation caused cytoplasmic translocation of PCBP2 post 8-h infection (Fig. 6a) . Moreover, the sumoylation inhibitor ginkgolic acid blocked the nuclear export of PCBP2 with VSV challenge (Fig. 6a) . As shown in the Fig. 5e , leptomycin B also blocked cytoplasmic translocation of sumoylated PCBP2 after VSV challenge. Consistently, a large amount of sumoylated PCBP2 appeared in the cytoplasm of macrophages post 8 h of VSV stimulation (Fig. 6b) , whereas only a little amount of sumoylated PCBP2 remained in the nucleus. Accordingly, MAVS underwent degradation in the cytoplasm of VSV-infected macrophages (Fig. 6b) . These observations were further validated by cellular fractionation (Fig. 6c) . In addition, sumoylated PCBP2 neither affect the interaction between MAVS and PCBP2, nor the association of RIG-I or MDA5 ( Supplementary Fig. 5a ).These data indicate that the sumoylated PCBP2 leads to its nuclear export during the progress of virus infection.
We next deleted PCBP2 in macrophages via a CRISPR/Cas9 approach ( Supplementary Fig. 5b-d) . We rescued WT-PCBP2 or K37R-PCBP2 in PCBP2-deleted macrophages. We observed that WT-PCBP2 restoration was able to cause the nuclear export of PCBP2 after VSV infection (Fig. 6d) . However, the K37R-PCBP2 mutant abolished such activity. Consistently, K37R-PCBP2 restoration impaired the sumoylation of PCBP2 (Fig. 6e) , which kept MAVS stability as that of empty vector-treated control cells. By contrast, WT-PCBP2 restoration still induced the sumoylation of PCBP2 and caused the cytoplasmic translocation of PCBP2 (Fig. 6e) , leading to degradation of MAVS. AIP4 has been reported to mediate MAVS ubiquitination in a PCBP2-dependent manner 16 . We noticed that PCBP2 sumoylation is required for AIP4 activation (Fig. 6f) . Cytoplasmic translocation of PCBP2 and IRTKS are also needed for MAVS degradation (Fig. 6g) . IRTKS-mediated MAVS degradation is AIP4 dependent (Fig. 6h) .
Notably, PCBP2 knockout markedly produced type I IFNs (Fig. 7a) . However, K37R-PCBP2 restoration did not suppress the production of IFN-b in PCBP2-deleted macrophages (Fig. 7a) , while WT-PCBP2 restoration inhibited the generation of IFN-b. Consequently, K37R-PCBP2 restoration still repressed the virus titres and replication rate as PCBP2 þ / þ cells ( Fig. 7b and Supplementary Fig. 5e ). These data indicate that the sumoylation of PCBP2 is involved in the regulation of MAVS-mediated virus clearance.
Notably, IRTKS deletion abrogated the nuclear export of PCBP2 after 8 h of VSV challenge (Fig. 7c) , suggesting that IRTKS played a critical role in the cytoplasmic translocation of PCBP2. As shown in Fig. 5b , the aa 1-230 fragment of IRTKS is necessary for association with Ubc9. To further confirm the critical role of IRTKS in PCBP2 sumoylation, we then rescued WT-IRTKS or D1-230-IRTKS in IRTKS À / À macrophages. We found that D1-230-IRTKS restoration did not cause the cytoplasmic translocation of PCBP2 after 8 h of VSV infection (Fig. 7d) . Accordingly, D1-230-IRTKS restoration did not suppress antiviral activity in IRTKS-deficient cells either (Fig. 7e) , suggesting a critical role of IRTKS in the sumoylation of PCBP2. Finally, D400-514-IRTKS restoration in IRTKS À / À macrophages did not induce the nuclear export of PCBP2 with VSV challenge either (Fig. 7f) . Consistently, D400-514-IRTKS restoration disrupted the PCBP2 sumoylation (Fig. 7g, upper panel) , and still sustained the stability of MAVS (Fig. 7g, lower panel) . Overall, IRTKS-mediated PCBP2 sumoylation is required for its cytoplasmic translocation that associates with MAVS, leading to MAVS degradation. leading to clearance of viruses. MAVS, an innate immune signalling adaptor, integrates signals from two independent cytosolic PRRs to trigger activation of IKK and TBK, which consequently activate NF-kB and IRF3 to induce production of type I IFNs 1 . Antiviral signalling activation is an extremely powerful cellular response that requires strict modulation to adequately eradicate invading viruses while avoiding damage to the cell from overzealous inflammation. In this study, we define that IRTKS as an inhibitory modulator for the RIG-I-MAVS signalling pathway. IRTKS can recruit the E2 ligase Ubc9 to sumoylate PCBP2 in the nucleus that causes its cytoplasmic translocation. In the cytoplasm, the sumoylated PCBP2 associates with MAVS to initiate MAVS degradation, leading to downregulation of host immune response (Fig. 8) .
On activation of the RLR signalling pathway, MAVS undergoes prion-like polymerization to form a MAVS signalosome 11, 12 , resulting in activation of the cytosolic kinases IKK and TBK1. In this process, many factors of the host tightly regulate the RIG-I-MAVS signalling pathway to balance the virus infection-elicited inflammation. It has been reported that some viruses, including hepatitis C virus and enterovirues, employ their endogenous proteinases to directly cleave MAVS 8, 36, 37 , leading to the 17) , have been identified to ubiquitinate MAVS for its degradation. PCBP2 could be act as a physical scaffold to link MAVS with its E3 ligases for its ubiquitination 17 . Notably, PCBP2 resides mainly in the nucleus in a steady state. However, it is unknown how PCBP2 relocalizes to the cytosol where it associates with MAVS on virus infection. Herein, we show that IRTKS negatively regulates antiviral responses against RNA viruses in a RIG-I-MAVSdependent manner. PCBP2 sumoylation mediated by IRTKS took place in the nucleus on RNA virus infection, which causes its cytoplasmic translocation to interact with MAVS during the late stage of infection, leading to MAVS degradation. PCBP2 sumoylation and IRTKS are required for AID4-mediated MAVS degradation. Moreover, MDA5 expression increases Ifnb expression only at late time of VSV infection, which is in agreement with recent reports 28, 29 . These observations suggest that IRTKS might play a role at the early time points of the antiviral response that is RIG-I mediated. Therefore, the PCBP2 sumoylation plays a critical role in IRTKS-mediated suppression of antiviral activity against RNA viruses.
Protein sumoylation plays an important role in various cellular processes, including cell proliferation, apoptosis, transcription regulation and so on 40, 41 . Like the ubiquitin system, the SUMO system targets a large number of proteins to fulfil numerous functions 42, 43 . However, the salient difference from the ubiquitin system is the simplicity of the enzymatic apparatus for sumoylation and de-sumoylation. Up to date, only one SUMOconjugating enzyme Ubc9 has been identified 41 . In this study, we demonstrate that IRTKS can recruit Ubc9 to sumoylate PCBP2 at Lys37 in the nucleus during the early stage of RNA virus infection. Over the process of RNA virus infection, sumoylated PCBP2 causes its cellular switch for nuclear versus cytoplasmic localization, where the sumoylated PCBP2 associates with MAVS to initiate its degradation. The sumoylation inhibitor or Ubc9 depletion abolishes the sumoylation of PCBP2, indicating that PCBP2 is a novel substrate for sumoylation during RNA virus infection.
In the inner membrane compartment, IRTKS regulates bundles of actin filaments 20 . During intracellular bacterial infection, bacteria utilize the cytoplasmic actin activators to generate pathogen-driven actin pedestal right after the bacterial invasion 22 . IRTKS can be directly activated by the tyrosine kinase Src through phosphorylation, leading to enhanced cell migration 44 . In addition, IRTKS can interact with the epidermal growth factor receptor to activate the ERK signalling, which is involved in the pathogenesis of hepatocellular carcinoma 45 . Our recent report showed that IRTKS is phosphorylated in response to insulin stimulation, whose deletion causes insulin resistance 23 . Insulin resistance might be implicated in clinical infections and immune regulations. Herein, we show that IRTKS deficiency does not influence the antibacterial response in mice. Quite interestingly, IRTKS-deficient mice exhibit elevated antiviral activities against RNA viruses, but not DNA viruses. However, the underlying mechanism of IRTKS-mediated immune suppression in response to distinct viruses needs to be further investigated.
IRTKS was originally cloned from endocrine organs 46 . As an insulin receptor tyrosine substrate, IRTKS is phosphorylated after activation of insulin signalling 20 . Insulin, as the primary anabolic hormone, modulates a variety of physiological processes, including growth, differentiation, apoptosis, as well as synthesis and breakdown of lipid, protein and glucose 47 . Insulin binds to its insulin receptor to activate the receptor intrinsic tyrosine kinases, leading to activation of the PI3K/Akt pathway 48, 49 . Insulin signalling is indispensable for glucose metabolism in cells of the muscle and adipose tissues 50 . We previously demonstrated that IRTKS-deficient mice display hyperglycaemia, hyperinsulinaemia, glucose intolerance and decreased insulin sensitivity 23 , suggesting IRTKS is implicated in the pathogenesis of diabetes. The pathogenesis of diabetes might be closely related to excessive autoimmune responses 51 . However, the mechanism leading to autoimmunity in diabetes still remains elusive. Recent onset of type 1 diabetes is strongly correlated with infection by RNA viruses such as enteroviruses 52, 53 . Moreover, a transcriptional signature of type I IFNs precedes islet autoimmunity 54 . Type I IFNs play a critical role in many autoimmune diseases via various immune modulatory actions 55 . We show that IRTKS targets the RIG-I-MAVS signalling axis that modulates the production of type I IFNs as a negative modulator in infection of RNA viruses. Furthermore, IRTKS-mediated immune suppression differs in response to different types of viruses. Thus, our findings will prompt us to further investigate the connection of IRTKS between the virus infections and the pathogenesis of autoimmune diseases.
Methods
Antibodies and reagents. Antibodies used were: anti-IRTKS and anti-EEA1 were from Santa Cruz Biotechnology; anti-IRF3, anti-MAVS, anti-K48-polyubiquitin, anti-H3 and anti-Ubc9 were from Cell Signaling Technology; anti-PCBP2 and anti-SUMO2 were from MBL International Corporation; anti-GST, anti-green fluorescent protein (GFP), anti-HA, anti-FLAG, anti-b-actin and anti-His antibodies were from Sigma-Aldrich; Donkey anti-rabbit or anti-mouse secondary antibodies conjugated with Alexa-488, Alexa-594 or Alexa-405 were purchased from Molecular Probes. HRP-conjugated secondary antibodies were from Santa Cruz Biotechnology. Paraformaldehyde, cycloheximide, MG132, ginkgolic acid, isopropyl-b-D-thiogalactopyranoside, 4,6-diamidino-2-phenylindole and propidiumiodide were from Sigma-Aldrich.
Cells and culture. For BMDMs, bone marrow cells were aspirated from mouse femurs, followed by culture in RPMI 1640 media containing 10% fetal bovine serum, 50 ng ml À 1 macrophage colony stimulating factor (MCSF) for 7 days. For macrophage transfection, BMDMs (1 Â 10 6 ) were resuspended in 100 ml Nucleofector solution buffer (Lonza) containing 5 mg RNA or other substrates, followed by transfection using the Nucleofector Program Y-001 on Amaxa nucleofector II device (Lonza). Cells were recovered in RPMI 1640 media containing 4 mM Lglutamine, 1.5 g l À 1 sodium bicarbonate and 10% heat-inactivated fetal bovine serum for 6 h, followed by flow cytometric sorting for viable cells.
Animals and viruses.
Mouse experiments complied with ethical regulations and were approved by the Institutional Animal Care and Use Committees at the Institute of Biophysics, Chinese Academy of Sciences. IRTKS mice were generated through embryo injection of embryonic stem cells with a complete deletion of exon 1 of IRTKS provide by Shanghai Bimodal Organism Science & Technology Development 23 . IRTKS knockout mice were backcrossed to C57BL/6 background for more than six generations. Female mice at an age of 12 weeks were used in this study. For preparation of viruses, viruses were incubated with Vero cells, followed ARTICLE by supernatant collection 48 h later. SeV viruses were cultured in embryonated eggs. Supernatants were ultra-centrifuged at 25,000g for 2 h. Pellets were resuspended in RPMI 1640. For virus infection in vivo, mice were either intravenously injected with viruses or intranasally inoculated with viruses for long time observation.
Plasmid construction. SAE1, SAE2, Ubc9, SUMO2, IRTKS, PCBP2, RIG-I and MDA5 were cloned from a murine bone marrow library 29 . MAVS (also known as VISA) was a gift from Hongbing Shu (Wuhan University). SAE1, SAE2, Ubc9 andSUMO2 were subcloned into pET-28a vectors for His-tagged protein expression.PCBP2 and IRTKS were subcloned into pFlag-CMV2 or pCMV-HA for expression in mammalian cells. PCBP2 and IRTKS were also subcloned into pGEX-6p-1 for GST-fusion protein expression in Escherichia coli.
ELISA-based interferon determination. Supernatants from cultured cells or sera were collected at the indicated times. Cytokines were analysed by ELISA kits (R&D Systems) with the manufacturer's instructions.
Luciferase assay. IFN-b luciferase reporter was constructed as described 26 . Luciferase reporter vectors were co-transfected with pRL-TK (as an internal control reporter vector) into MEF cells by electroporation. Luciferase assays were performed with guidelines provided by the manufacturer (Promega).
Yeast two-hybrid screening. Yeast two-hybrid screening was performed as described previously 56 . Briefly, IRTKS was cloned into pGBKT7 vector (BD-IRTKS). Yeast AH109 cells were transfected with BD-IRTKS and plasmids containing a mouse bone marrow cDNA library (Clontech/Takara) and then plated on selective synthetic defined (SD) media. Selected clones were isolated for DNA sequencing. X-a-gal assay was carried out by the manufacturer's instructions.
Immunoprecipitation. Cells were collected and treated with lysis buffer (150 mM NaCl, 50 mM Tris-Cl, 1% Triton X-100, protease inhibitor cocktail, pH 7.4). Supernatants were collected by centrifugation (15,000g, 15 min, 4°C), and incubated with the indicated antibodies (1 mg ml À 1 ) for 6 h at 4°C, followed by immunoprecipitation with 20 ml protein A/G conjugated agarose (Santa Cruz Biotechnology). The precipitates were completely washed with lysis buffer and detected through immunoblotting.
Immunofluorescence. Immunostaining was performed as described previously 57, 58 . Briefly, cells were plated on 0.01% poly-L-Lysine-treated coverslips and fixed with 4% paraformaldehyde for 10 min, followed by permeabilization with 0.5% Triton X-100 for 20 min at room temperature. Primary antibodies (0.2 mg ml À 1 ) were added for 2 h at room temperature post blocking with 10% donkey serum for 30 min. Samples were further stained with Alexa-488-, Alexa-594-or Alexa-405-conjugated secondary antibodies, followed by visualization with confocal microscopy (Olympus FV1000).
RNA interference. RNA interference sequences were designed according to pSUPER system instructions (Oligoengine). BMDMs were electroporated with pSUPER-GFP vector encoding target sequences against PCBP2 (#1: Reverse transcription-PCR analysis. Total RNA was extracted from cells using Trizol reagent and cDNA was reverse transcribed using Superscript II (Invitrogen). Reverse transcription-PCR (RT-PCR) was performed using StarScript II Two-step RT-PCR Kit (Genestar) with the following primers: Ifna primers, sense: 5 0 -ACTC ATAACCTCAGGAACAAG-3 0 , anti-sense: 5 0 -CTTTGATGTGAAGATG TTC AG-3 0 ; Ifnb primers, sense: 5 0 -AGTACAACAGCTACGCCTGG-3 0 , anti-sense: 5'-GAGT CCGCCTCTGATGCTTA-3 0 ; Mavs, sense: 5 0 -GCGAGGTCCACTGAG CTATC-3 0 , anti-sense: 5 0 -CAGGTCAGGAGCAATGGAGG-3 0 ; Pcbp2, sense: 5 0 -TGGATGCCACAG TGACTTACG-3 0 , anti-sense: 5 0 -GGGAGGTGATTGAGG GCAAA-3 0 . VSV RNA was detected as described 59 .
In vitro sumoylation reconstitution assay. cDNAs of SAE1, SAE2, Ubc9, SUMO2, PCBP2 and IRTKS were subcloned into pET-28a vectors. Plasmids were transformed into E. coli strain BL21 (DE3). DE3 clones were cultured (OD 600 ¼ 0.6), followed by induction with 0.2 mM isopropyl-b-D-thiogalactopyranoside at 16°C for 24 h. Cells were collected and lysed by supersonic and further purified through Ni-NTA resin columns. The in vitro sumoylation reconstitution assays were performed by mixing SAE1/SAE2 (2 mg ml À 1 ), Ubc9 (1.5 mg ml À 1 ), SUMO2 (1 mg ml À 1 ) and other proteins in the SUMO buffer (50 mMTris-HCl, 5 mM MgCl 2 , pH 8.0) to a volume of 18 ml. The reaction was started by adding 2 ml ATP buffer (2 mM ATP, 10 mM creatine phosphate disodium salt, 3.5 U ml À 1 creatine kinase, 0.6 U ml À 1 inorganic pyrophosphatase) at 37°C for 2 h.
Gene knockout in BMDMs through CRISPR-Cas9 technology. Genome engineering of the indicated genes was performed using the CRISPR-Cas9 system as described 60 . sgRNA upstream of PCBP2 exon 2: 5 0 -ACCATTACCAGTGG AATGGT-3 0 , sgRNA downstream of PCBP2 exon 2: 5 0 -CTTTTCTAGTGGAG TGTGGT-3 0 . WT BMDMs were infected with lentivirus to introduce the GFP-containing CRISPR/Cas9 vectors. GFP high cells were sorted through flow cytometry, followed by analysis of editing efficiency through PCR. PCR products were subcloned and genotyped by DNA sequencing. Genotyped cells were transplanted to recipient mice for further experiments.
Statistical analysis. Statistical significance was calculated by the indicated test as described in figure legends by GraphPad Prism 5.
